Surgical treatment for peritoneal carcinomatosis from gastric cancer

European Journal of Surgical Oncology

Volumn 36, Issue 12, 2010, Pages 1131-1138

  Yonemura, Y ^a   Endou, Y ^b   Sasaki, T ^c   Hirano, M ^d   Mizumoto, A ^d   Matsuda, T ^d   Takao, N ^d   Ichinose, M ^d   Miura, M ^e   Li, Y ^f  

^a NPO Organization to Support Peritoneal Dissemination Treatment   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d Kusatsu General Hospital   (Japan)

^e OITA UNIVERSITY   (Japan)

^f WUHAN UNIVERSITY   (China)

Author keywords

Cytoreductive surgery; EPIC; Gastric cancer; NIPS HIPEC; Peritoneal carcinomatosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PIRARUBICIN; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; EARLY POSTOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAP; LAPAROSCOPY; MONOTHERAPY; MORBIDITY; NEOADJUVANT INTRAPERITONEAL SYSTEMIC CHEMOTHERAPY; NONHUMAN; PERITONEUM LAVAGE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH CANCER; SURGICAL MORTALITY; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; HYPERTHERMIC THERAPY; INFUSION; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; PATHOLOGY; PERITONEUM TUMOR; STOMACH TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; LAPAROSCOPY; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; PERITONEAL LAVAGE; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 79952064960     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.09.006     Document Type: Review

References (60)

1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Freig WE. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9. (Pubitemid 46630593)
2. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative group. J Clin Oncol 2000; 18:2648-57. (Pubitemid 30465650)
3. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin and fluorouracil; Docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil As systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss group for clinical cancer research. J Clin Oncol 2007;25:3217-23. (Pubitemid 47325604)
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006;24:4991-7. (Pubitemid 46631401)
5. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4M gimestat-1 M ostat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20. (Pubitemid 28474225)
6. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
7. Imamura H, Hishi H, Tsuburaya A et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer. (GC0301/TOP-002). Asco gastrointestinal Symposium, abstract #5, 2008.
8. Ross P, Nicolson M, Valle J, et al. Prospective randomized trial comparing Mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004. (Pubitemid 34413593)
9. Koichi M, Fujii M, Kanamori N, et al. Neoadjuvant chemotherapy with S-q and CDDP in advanced gastric cancer. J Cancer Res Clin Oncol 2006;132:781-5. (Pubitemid 44521453)
10. Yabusaki Y, Nashimoto A, Tanaka O. Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer. Jpn J Cancer Chemother 2003;30:1933-40.
11. Baba H, Yamamoto M, Endo K, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 2003;6:45-9. (Pubitemid 36604656)
12. van der SpeetenK Stuart OA, Sugarbaker PH. Using pharmacologic data to plan clinical treatment for patients with peritoneal surface malignancy. Curr Drug Discov Technol 2009;6:P72-81.
13. Park JG, Kramer B, Steinberg SM, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a Tetrazolium-based colorimetric assay. Cancer Res 1987;47:5875-9. (Pubitemid 18018721)
14. Yonemura Y, Endou Y, Bando E, et al. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Let 2004;16189-96.
15. Shimada T, Nomura M, Yokogawa K, et al. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol 2005;57: 177-81. (Pubitemid 40129084)
16. Yonemura Y, Endou Y, Tochiori S, et al. Effects of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer. Gan to Kagaku Ryoho 2005;32:1635-9.
17. Marchettini P, Stuart A, Mohamed F, et al. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 2002;49: 499-503. (Pubitemid 34671286)
18. Los G, Mutsaers PHA, van der Vijgh WJ, et al. Direct diffusion of cisdiamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380-4. (Pubitemid 19162154)
19. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of Adriamycin penetration in murine ovarian cancer. Cancer Res 1979;43: 3209-14. (Pubitemid 9231829)
20. Yano M, Shiozuka H, Inoue M, et al. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. World J Surg 2002;26:1155-9. (Pubitemid 36920275)
21. Yabusaki H, Nashimoto A, Tanaka O, et al. Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer. Gan to Kagaku Ryoho 2003;30:1933-40.
22. Inokuchi M, Yamashita T, Yamada H, et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Brit J Cancer 2006;94:1130-5.
23. Armstrong DK, Wenzel BB, Huang HQ, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;5:34-43. (Pubitemid 43048949)
24. Yonemura Y, Shinbo M, Hagiwara A, et al. Treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells. Gastroenterological Surg 2008;31:802-12. [in Japanese].
25. Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. EJSO 2006;32:661-5. (Pubitemid 44063995)
26. Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointetinal Oncol 2010;2:85-97.
27. Verwaal VJ, Bruin A, Boot H, et al. 8-Year follow-up of randomized trial:cytoreduction and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2633-5.
28. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multiinstitutional study. J Clin Oncol 2004;22:3284-92. (Pubitemid 41103684)
29. Yamamura Y, Ito H, Mochizuki Y, et al. Distribution of free cancer cells in the abdominal cavity suggests limitation of bursectomy asa an essential component of radical surgery for gastric cancer. Gastric Cancer 2007;10:4-8.
30. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-6. (Pubitemid 38049613)
31. Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. [Epub ahead of print]. Ann Surg Oncol. 2010;25. [Epub ahead of print].
32. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 2009;100:311-6.
33. Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Brit J Surg 2005;92:370-5. (Pubitemid 40445602)
34. Sugarbaker PH. Peritonectomy Procedures Ann Surg 1995;221:29-42.
35. Yonemura Y, Kawamura T, Bandou E, et al. The natural history of free cancer cells in the peritoneal cavity. In: Gonzalez-Moreno. S, editor. Advances in peritoneal surface oncology. Berlin: Springer; 2007, p. 11-23.
36. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49-58. (Pubitemid 26130826)
37. Esquivel J, Sticca R, Sugarbaker PH, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancy of colonic origin: a consensus statement. Society of Surgical oncology. Ann Surg Oncol 2007;14:128-33. (Pubitemid 44954279)
38. Stellengrebel HAM, Zoetmulder FAN, Sweenk RM, Antonini N, Verwaal VJ. Quantitative intra-operative assessment of peritoneal carcinomatosis- A comparison of three prognostic tools. EJSO 2009;35: 1078-84.
39. Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/ or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol 2010;101:459-64.
40. Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2003;12:454-63.
41. Yonemura Y, Mizumoto A, Ichinose M, et al. Peritonectomy procedures for peritoneal mesothelioma and pseudomyxoma peritonei. Operation 2009;63:1959-70.
42. Mohamed F, Marchettini P, Atuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10:463-8. (Pubitemid 40486946)
43. Verwaal V. Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J 2009;15:212-5.
44. YanTD, Black D, SugarbakerPH, et al.Asystemic reviewand meta-analysis of randomized controlled trial on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann Surg Oncol 2007;14:2702-13. (Pubitemid 47460649)
45. YonemuraY, Aletxabal X, Fujimura T, et al. Intraperitoneal chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study.Hepatogastroenterol 2001;48:1176-82.
46. Hirose K, Katayama K, Iida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer. Oncology 1999;57:106-14. (Pubitemid 29385487)
47. Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraperitoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009;250:242-6.
48. Koh JL, Yan TD, Glenn D, et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 2009;16:327-33.
49. Yan QM, Bando E, Kawamura T, et al. The diagnostic value of PETCT for peritoneal dissemination of abdominal malignancies. Gan to Kagaku Ryoho 2006;33:1817-21.
50. Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol 2006;32:625-7. (Pubitemid 44064002)
51. Ribeiro U, Gama-Rodrigues JJ, Safatle-Ribeiro AV, et al. Prognostic significance of intraperitoneal free cancer cells obtained by laparoscopic peritoneal lavage in patients with gastric cancer. J Gastrointest Surg 1998;2:244-9. (Pubitemid 128409610)
52. Badgwell B, Cormier JN, Krishnan S, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol 2008;15:2684-91.
53. Facchiano E, Scaringi S, Klanmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 2008;34:154-8.
54. Thomas F, Ferron G, Gesson-Paute A, et al. Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy 2008;15:3623-4.
55. Sugarbaker PH, Graves T, DeBruijin EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 1990;50:5790-4. (Pubitemid 20331378)
56. Jeung HC, Sy Rha, Jang WI, et al. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg 2002;89:460-6. (Pubitemid 34595512)
57. Elias D, Gilly F, Boutitie F, et al. Peritonea; colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicenter French study. J Clin Oncol 2010;28:63-8.
58. Yu W, Whang I, Chung HY, et al. Indication for early postoperative intraperitoneal chemotherapy for advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001;19:985-90. (Pubitemid 32747644)
59. Lanuke K, Mack LA, Temple WJ. Phase III study of regional treatment for peritoneal carcinomatosis. Am J Surg 2009;197:614-8.
60. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol 2009 Sep 15;100(4):311-6.